AUTHORS
Charan Thej Reddy Vegivinti, MD, MBBS, Arnav Ramnath Chatrathi2, Abdur Rehman3, Faezeh Darbaniyan, PhD4, Pranoti Sahasrabhojane5, Amishi Vora6, Donna Marie Weber, MD7, Melody Renee Becnel, MD8, Oren Pasvolsky, MD9, Sarvari V. Yellapragada, MD10, Mahmoud R. Gaballa, MD11, Sheeba Koshy Thomas, M.D.12, Jing Christine Ye, M.D., MSc13, Nadim Ajami14, Christopher R. Flowers Jr, MD, MS15, Krina Patel Jr, MD, MSc16, Elisabet Esteve Manasanch, M.D.17, Robert Orlowski, MD, PhD18, Neeraj Saini, MD19
AFFILIATIONS
1 The University of Texas MD Anderson Cancer, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer, Houston, Texas, United States
16 The University of Texas MD Anderson Cancer, Houston, Texas, United States
17 Regeneron pharmaceuticals, New York, New York, United States
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States, The University of Texas MD Anderson Cancer, Houston, Texas, United States
19 The University of Texas MD Anderson Cancer Center, Houston, Texas, Houston, Texas, United States, The University of Texas MD Anderson Cancer, Houston, Texas, United States
ABSTRACT
Introduction: High-fiber dietary intervention (NUTRIVENTION) in myeloma precursor disorders slows progression and expands butyrate-producing gut bacteria, implicating the microbiome in the MGUS-to-SMM transition. Whether the gut microbiome itself differs between monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) is unknown. We performed a comprehensive multi-omic stool microbiome comparison of MGUS versus SMM.
Method: Shotgun metagenomic sequencing was performed on 152 stool samples from 81 patients (MGUS, 33 patients/57 samples; SMM, 48/95). We profiled bacterial taxonomy (MetaPhlAn 4), microbial pathways and genes (HUMAnN 3.9), and the gut virome (vOTU catalog). Differential abundance testing used compositional (CLR) linear mixed models with a patient random effect and sequencing batch as a covariate, confirmed by Analysis of Composition of Microbiomes with bias correction (ANCOM-BC2). Exploratory discovery used Linear discriminant analysis effect size (LEfSe) and ordered-trend testing (Jonckheere-Terpstra) across the MGUS-low-risk SMM-high-risk SMM continuum.
Results: Overall, MGUS and untreated SMM did not show evidence of broad gut microbiome dysbiosis. No bacterial species (473 tested), pathway (445), viral OTU (9,475), or KEGG ortholog (42,108) reached significance after FDR correction by either CLR mixed models or ANCOM-BC2 (species minimum q=0.42 and 0.98, respectively). Alpha diversity did not differ (all p>0.6), and patient-level community structure showed no association with disease state (species Bray-Curtis R²=0.9%, virome R²=1.1%; both p>0.75). Together, these findings argue against a major global microbiome shift distinguishing MGUS from SMM.
However, beneath this largely negative result, exploratory analyses identified a biologically coherent signal involving specific butyrate-producing anaerobes. Several Firmicutes associated with butyrate production were less frequently detected in SMM than in MGUS, including Gemmiger formicilis (70% in MGUS vs 40% in SMM, LEfSe p=0.035, LDA-3.7), Faecalicatena contorta (64% vs 35%; p=0.007), and Lachnoclostridium sp. An138 (52% vs 27%; p=0.041); the CLR mixed model corroborated these directions.
When patients were ordered along the disease continuum from MGUS to low-risk SMM to high-risk SMM, Faecalicatena contorta and Anaerobutyricum hallii showed a monotonic decline in prevalence, while Gemmiger formicilis showed a decreasing trend (Jonckheere-Terpstra p = 0.006-0.04). These patterns were similar using both Mayo 2018 and Spanish/PETHEMA risk scores. Importantly, this was not a broad loss of butyrate-producing capacity. Aggregate butyrate-producer abundance and predicted butyrate-synthesis capacity were unchanged (p>0.2). Thus, the signal appears to reflect loss of specific commensal anaerobes rather than loss of the entire community’s ability to produce butyrate.
Conclusions: MGUS and SMM showed broadly similar gut microbiome profiles, arguing against gross dysbiosis as a defining feature of early plasma-cell disorder progression. This is biologically plausible because these precursor states evolve slowly and generally precede the intensive therapies, antibiotics, and hospital exposures that later drive major microbiome disruption in myeloma. Instead, our exploratory analyses identify a more focused signal: selective depletion of specific butyrate-producing anaerobes, led by Gemmiger formicilis, across the MGUS-to-SMM continuum. This finding is hypothesis-generating and concordant with NUTRIVENTION and other butyrate-centered diet-microbiome data. These results nominate butyrate-producing species and butyrate biology for mechanistic validation in myeloma-prone models and larger longitudinal cohorts.
DISCLOSURES
Charan Thej Reddy Vegivinti, MD, MBBS: No relevant conflicts of interest to declare.